225Ac-Satoreotide is a first-in-class somatostatin receptor 2 antagonist targeting extensive stage small cell lung cancer and is the first antagonist labelled with 225Ac to enter clinical developmentSatoreotide expressed a superior pharmacokinetic profile relative to DOTA-TATE with a higher pre-clinical anti-tumour efficacy, irrespective of radionuclide used100% survival with a single dose of 30 kBq 225Ac-satoreotide but not with 225Ac-DOTA-TATEBERLIN, Oct. 22, 2024 /PRNewswire/ — Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announces that it presented data on its proprietary radiolabelled peptide SS0110 (satoreotide), a first-in-class antagonist of the somatostatin receptor 2 (SSTR2), at this year’s European Association of Nuclear Medicine (EANM) Annual Conference, held in Hamburg, Germany from 19-23 October 2024.

The Top-Rated Oral Presentation (TROP) entitled ‘225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts’, details the anti-tumour efficacy of different radiolabelled satoreotide antagonists (225Ac, 161Tb, 177Lu-labelled SSO110) versus respective DOTA-TATE agonists (225Ac- and 161Tb-labelled DOTA-TATE) in mice engrafted with SSTR2 positive xenografts of small cell lung cancer (SCLC) and pancreatic cancer using clinically relevant associated dose ranges.  
Results demonstrate that 225Ac-satoreotide shows the strongest anti-tumoural effect in vivo at a low single dose when evaluating satoreotide and DOTA-TATE radiolabelled with different radionuclides. Irrespective of the radionuclides used, satoreotide demonstrated a higher pre-clinical anti-tumour efficacy when compared to DOTA-TATE which was less potent and required increased dose levels. Satoreotide was well tolerated across all dose levels and with all used radionuclides. These comparisons between satoreotide and DOTA-TATE will facilitate and guide further clinical development of satoreotide across multiple indications expressing SSTR2, such as SCLC, pancreatic cancers and Merkel Cell Carcinoma (MCC).
Previous comparisons between satoreotide and DOTA-TATE demonstrated that antagonist, 225Ac-satoreotide, is multiple times more potent than SSTR2 agonist, 225Ac-DOTA-TATE, signifying a durable complete response in standard murine xenograft models of SCLC in animal models, versus tumour growth delay.
Ariceum had previously shown at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting 2024 that 212Pb was not seen to be more potent than Lutetium or Terbium but caused more side effects and hence was not further pursued.
Manfred Rüdiger, Chief Executive Officer at Ariceum Therapeutics, said: “These results provide strong evidence for satoreotide and its potential to clinically outperform SSTR2 targeting agonists, by demonstrating significantly better efficacy in tumour growth control, up to complete tumour eradication depending on isotope used. In addition, when a single dose of 30 kBq 225Ac-satoreotide was administered, we observed high frequency of complete durable responses and 100% survival which strongly supports further clinical development for the treatment of SCLC, MCC and other cancers.”
Details of the oral presentation are as follow:
Title: 225Ac-SSO110 induces long-lasting anti-tumour responses in contrast to 225Ac-DOTA-TATE and 161Tb-DOTA-TATE in the treatment of SSTR2-positive tumour xenografts
Presenting Author: Prachi Desai, Scientist at Ariceum Therapeutics
Session Number: 1204Session Title: M2M Track – TROP Session: Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: From Radionuclide to Clinical Translation
Oral Presentation Date & Time: Tuesday 22 October 2024, 09:00 AM – 09:10 AM CEST
Abstract Authors: Prachi Desai, Manuel Sturzbecher –  Hoehne, Dennis Mewis, Manfred Ruediger & Anika Jaekel  of Ariceum Therapeutics
Abstracts are available in the September edition of Springer’s European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) abstract book here and on the Ariceum website here.
About Ariceum Therapeutics
Ariceum Therapeutics (Ariceum) is a private, clinical stage radiopharmaceutical company focused on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. The name Ariceum is an anagram of ‘Marie Curie’ whose discovery of radium and polonium have been huge contributions to finding treatments for cancer.
Ariceum’s lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (“Satoreotide”), is an antagonist of the somatostatin type 2 (SSTR2) receptor which is overexpressed in neuroendocrine tumours (NETs) and some aggressive cancers such as small cell lung cancer (SCLC), or Merkel Cell Carcinoma (MCC), all of which have few treatment options and poor prognosis. Satoreotide is being developed as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of these tumours. Ariceum is also developing a radiolabelled PARP-inhibitor (ATT001), currently in Phase 1 clinical development under the trial name CITADEL-123. ATT001 was part of the acquisition of Theragnostics Ltd which was closed in June 2023.
Ariceum Therapeutics, launched in 2021, acquired all rights to Satoreotide from Ipsen. Ipsen remains a shareholder in the Company. Ariceum is headquartered in Berlin, with operations in Germany, Switzerland, Australia, United Kingdom and United States of America and with activities currently across the globe.
Ariceum is led by a highly experienced management team and supported by specialist investors including EQT Life Sciences (formerly LSP), HealthCap, Pureos Bioventures, Andera Partners and Earlybird Venture Capital. For further information, please visit www.ariceum-therapeutics.com.
About European Association of Nuclear Medicine (EANM)
The European Association of Nuclear Medicine (EANM) is a non-profit organization that promotes nuclear medicine and aims to improve public health. The EANM’s mission is to advance nuclear medicine through personalized healthcare, innovation in diagnosis and treatment, and raising awareness of nuclear medicine

View original content:https://www.prnewswire.co.uk/news-releases/ariceum-therapeutics-presents-outstanding-data-on-its-first-in-class-radiopharmaceutical-drug-225ac-satoreotide-at-the-european-association-of-nuclear-medicine-2024-302282011.html

PRYZM to refer and implement Trintech’s market-leading cloud-based finance and accounting solutions
LONDON, Oct. 22, 2024 /PRNewswire/ — Trintech, a leading global provider of cloud-based financial close solutions for the Office of Finance, today announced a strategic partnership with PRYZM, a leading consultancy specializing in Finance Transformation and Enterprise Performance Management (EPM) solutions. The partnership enables PRYZM to offer and implement Trintech’s market-leading cloud-based finance and accounting solutions to businesses in EMEA and beyond. Companies looking to transform and automate their reconciliation and financial close processes by streamlining work, improving accuracy, and reducing risk, will benefit from the combination of services and solutions PRYZM and Trintech can provide.

“We are excited to formalize our partnership with PRYZM as we continue to expand Trintech’s partner ecosystem across the globe to better serve our new and existing customers,” said Scott Vipond, Managing Director, EMEA of Trintech. “Together, Trintech and PRYZM share a common goal in providing organizations with a holistic business vision and strategy to reduce costs, drive efficiencies and mitigate risk across their reconciliation and financial close processes.”
From high volume transaction matching, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, and close management tasks, to governance, risk and compliance – Trintech’s portfolio of financial solutions, including its Cadency® Platform (for large enterprises) and Adra® Suite (for mid-market organizations), help manage all aspects of the reconciliation and financial close processes.
“At PRYZM, we’re thrilled to partner with Trintech to support our clients’ journey in transforming finance processes,” said Dimitrios Christodoulopoulos, Founder & CEO of PRYZM. “With Trintech’s solutions, we can help companies simplify complex reconciliations, enhance visibility across accounts, and ensure accuracy in financial reporting. As businesses increasingly rely on advanced technology to streamline finance operations, our collaboration with Trintech enables us to provide organizations with precise, automated tools that deliver both control and efficiency across their accounting processes.”
To discover how this strategic partnership can help your organization streamline and accelerate reconciliation and financial close processes, visit www.pryzm.global or contact us for more information.
About PRYZM
PRYZM helps CFOs reimagine their Finance function by solving complex problems and accelerating their digital transformation journey. Through our services, we help organizations harness technology and innovation to shape their visions, execute their strategies and reinvent their businesses in order to achieve exceptional, sustainable value from their technology investments.
Contact: Dimitrios Christodoulopoulos Founder & CEO [email protected] 
About Trintech
Trintech gives people time back for what matters most. Our cloud–based platform and solutions enable thousands of clients worldwide to lead productivity transformation across their finance and accounting organizations — driving efficiencies, ensuring accuracy to mitigate risk, and empowering strategic decision-making. Make time count with Trintech.
As the leader in Financial Close Management, Trintech is headquartered in Plano, Texas with offices and strategic resellers across United States, Europe, Australia, South America, Africa, and Asia Pacific. With a strong partner ecosystem, Trintech collaborates with over 100 companies to create a network of interconnected businesses. To learn more about Trintech, visit www.trintech.com.
Media Contact: Kelli Shoevlin Director, Global Corporate Marketing & Communications [email protected] 
Logo – https://mma.prnewswire.com/media/2161503/Trintech_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/trintech-and-pryzm-announce-strategic-partnership-to-transform-and-automate-finance-and-accounting-processes-302282093.html

LINKÖPING, Sweden, Oct. 22, 2024 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra’s (STO: SECT B) SaaS in the cloud, Sectra One Cloud, will be used by Barking, Havering and Redbridge University Hospitals NHS Trust (BHRUT) in the UK as they join Homerton Healthcare’s current cloud solution for medical imaging. By using one unified platform the current cooperation between the hospitals will be enhanced which is anticipated to improve workflow and production at lower cost. Moreover, it will relieve BHRUT’s IT burden and costs for IT as Sectra takes full responsibility for the technology and operation of the system.

Since 2015, BHRUT has been using Sectra’s radiology solution. Operating from King George Hospital in Ilford and Queen’s Hospital in Romford, BHRUT serves the communities of Barking, Dagenham, Havering, and Redbridge in East London and Essex. As a part of the same hospital region as Homerton Healthcare—which adopted Sectra’s cloud service in 2023—BHRUT collaborates continuously with Homerton.
“We cooperate extensively with Homerton to ensure the patients in our region receive timely care, and therefore see huge benefits of further facilitating that collaboration. By having a joint Sectra solution, our radiologists will have immediate access to each other’s images and patient data, which will make it easier for us to collaborate around patient cases,” says David Newey, Interim Chief Digital Transformation Officer at BHRUT.
Sectra will provide BHRUT with a fully managed cloud service and continuously monitor, optimize, and upgrade the solution, as well as provide 24/7 support to ensure a smooth experience over time. This will create a comprehensive system at BHRUT, designed to accommodate potential growth as volumes increase and as potential expansion into other specialties is explored.  
“As Sectra takes responsibility for the operation and maintenance of the system, the resilience of the service we provide to our patients will improve, whilst our maintenance overhead will be reduced,” Newey adds.
The contract for Sectra One Cloud was signed in the second quarter of Sectra’s 2024/2025 fiscal year and BHRUT will initially use the modules for radiology and breast imaging.
“An increasing number of hospitals are transitioning to cloud-based solutions to enhance security and reduce IT burdens. This shift addresses the widespread challenge of shortages in IT staff required to manage hospital systems. Therefore, we are proud to provide BHRUT with a solution that relieves this significant burden. We are looking forward to continuing to support them and to enhance their cooperation with Homerton for improved patient care in the region,” says Jane Rendall, managing director for Sectra UK and Ireland.
Sectra’s enterprise imaging solution provides a unified strategy for all imaging needs while lowering operational costs. The scalable and modular solution, with a VNA at its core, allows healthcare providers to grow from ology to ology and from enterprise to enterprise. Visit Sectra’s website to read more about Sectra and why it’s top-ranked in “Best in KLAS”.
About Sectra
Sectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2023/2024 fiscal year totaled SEK 2,964 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra  AB, 46 (0) 705 23 52 27 Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/sectra/r/university-hospitals-in-the-uk-join-homerton-healthcare-s-public-cloud-service-from-sectra-enhances-,c4053880
The following files are available for download:
https://news.cision.com/sectra/i/sectra-s-radiology-module,c3343951
Sectra’s radiology module
 

View original content:https://www.prnewswire.co.uk/news-releases/university-hospitals-in-the-uk-join-homerton-healthcares-public-cloud-service-from-sectraenhances-collaboration-for-improved-care-302282763.html